Thermo Fisher Scientific Inc. cash flow to debt ratio of 19.85% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Thermo Fisher Scientific Inc.'s free cash flow has decreased 13.40% from $7.27B last year to $6.29B, signaling decreasing performance

Thermo Fisher Scientific Inc.'s debt to equity ratio is 0.81, which means that the company's assets are unhealthy financed, signaling financial risk.

Thermo Fisher Scientific Inc.'s debt has increased relative to shareholder equity from 0.66 last year to 0.81 today, signaling weakened financials

Thermo Fisher Scientific Inc. has a net debt to EBITDA ratio of 2.55x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Thermo Fisher Scientific Inc.'s interest coverage ratio of 5.59 indicates that earnings with good margin can cover interest payments on company debt

Thermo Fisher Scientific Inc.'s profit margin has increased (1.93%) in the last year from 14.77% to 15.06%, signaling increasing performance

Thermo Fisher Scientific Inc.'s short-term assets of $28.71B exceed its short-term liabilities of $15.19B

Thermo Fisher Scientific Inc.'s return on assets of 6.17% is higher than the 5.00% threshold, indicating efficient asset utilization

Thermo Fisher Scientific Inc.'s return on equity of 13.35%, is lower than 15.00%, indicating bad performance

Thermo Fisher Scientific Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Thermo Fisher Scientific Inc. had positive net income in 5 out of 5 years, indicating stable and consistent earnings

Thermo Fisher Scientific Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Thermo Fisher Scientific Inc. has a free cash flow yield of 2.82%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Thermo Fisher Scientific Inc.'s yearly earnings has increased 6.35% since last year from $6.33B to $6.74B, signaling increasing performance

Thermo Fisher Scientific Inc.'s yearly revenue has increased 3.91% since last year from $42.88B to $44.56B, signaling increasing performance

ROIC 7.44% (Source: FMP key-metrics). In the 5–10% partial-credit band. Score: 1 of 2. This band sits within the typical US weighted-average cost of capital range. Methodology choice can change the conclusion: under FMP's invested-capital definition the company is at or near its cost of capital; under narrower operating-capital definitions the same company may score higher. Invested capital here includes equity, non-current liabilities, and short-term debt. Cash is not subtracted. See methodology.

Thermo Fisher Scientific Inc.'s 3-year revenue CAGR of -0.27% is negative, indicating declining revenue over the past 3 years

Thermo Fisher Scientific Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Thermo Fisher Scientific Inc. had positive ROE in 5 out of 5 years, indicating consistent and reliable returns on equity

Thermo Fisher Scientific Inc. is overvalued relative to its fair value price of 101.78 based on Discounted Cash Flow model

Thermo Fisher Scientific Inc. has an earnings yield of 3.14%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

Thermo Fisher Scientific Inc. is overvalued relative to its fair value price of 132.57 based on EBITDA multiple model

Thermo Fisher Scientific Inc. has an EV/EBITDA ratio of 21.99x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

Thermo Fisher Scientific Inc. is overvalued relative to its fair value price of 432.18 based on Earnings Fair Value model

Thermo Fisher Scientific Inc. has a PEG-ratio over 1 which is considered overvalued

Thermo Fisher Scientific Inc. has a price-to-book ratio of 4.22x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Thermo Fisher Scientific Inc. has a price-to-sales ratio of 4.80x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue